{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017958", "CSN": null, "TRF": "ORD_1273243_01", "MRN": "37657548", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1011669", "clinicalId": "1013053", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1273243_01", "SampleName": "US1223101.01", "Version": "0", "Sample": {"FM_Id": "ORD_1273243_01", "SampleId": "US1223101.01", "BlockId": "nan", "TRFNumber": "ORD_1273243_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2021_12_31", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "Elevated Tumor Fraction Not Detected", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98148", "MRN": "37657548", "FullName": "\u5f35\u5c55\u9d3b", "FirstName": "Hung_Chan", "LastName": "Chang", "SubmittedDiagnosis": "Cholangiocarcinoma (From clincal diagnosis)", "Gender": "Male", "DOB": "1954_04_16", "OrderingMD": "\u8cf4\u5cfb\u6bc5", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2021_12_29", "ReceivedDate": "2022-01-19 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Cholangiocarcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "16", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "CARD11", "isVUS": "true", "variantName": "T532M"}, {"geneName": "CD22", "isVUS": "true", "variantName": "S137F"}, {"geneName": "CHEK2", "isVUS": "true", "variantName": "A98T"}, {"geneName": "KDM5A", "isVUS": "true", "variantName": "A1305D"}, {"geneName": "MAP2K2 (MEK2)", "isVUS": "true", "variantName": "P298L"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "Q473R"}, {"geneName": "POLD1", "isVUS": "true", "variantName": "G143D"}, {"geneName": "POLE", "isVUS": "true", "variantName": "I1864M"}, {"geneName": "PPP2R2A", "isVUS": "true", "variantName": "D23V"}, {"geneName": "RICTOR", "isVUS": "true", "variantName": "R910H"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "FGFR2", "Include": "true", "Alterations": {"Alteration": [{"Name": "GRM4_FGFR2 rearrangement", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "GRM4_FGFR2 rearrangement"}}, "Interpretation": "FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 fusions retaining the kinase domain encoded by exons 11_17 have been reported to be activating, oncogenic, and sensitive to FGFR inhibitors (Singh et al., 2012; 22837387, Lorenzi et al., 1996; 8799135, Wu et al., 2013; 23558953, Arai et al., 2013; 24122810, Wu et al., 2013; 23558953). Furthermore, FGFR2 variants lacking a portion of the cytoplasmic domain encoded by exon 18 have been reported to be oncogenic in vitro (Lorenzi et al., 1997; 9266968, Lorenzi et al., 1996; 8799135, Ueda et al., 1999; 10626794, Wu et al., 2013; 23558953, Cha et al., 2009; 19103595). Rearrangements such as observed here are predicted to be activating. Rearrangements such as observed here, those that are detected as a reciprocal fusion, are not clearly in frame, or may lack a fusion partner, may be indicative of an activating rearrangement event such as a fusion; however, it is unclear whether such rearrangements would lead to an oncogenic FGFR2 fusion. FGFR2 fusions have been reported in 10_50% of intrahepatic cholangiocarcinoma patients (Ross et al., 2014; 24563076, Borad et al., 2014; 24550739, Arai et al., 2013; 24122810) and have also been observed in colorectal cancer, hepatocellular carcinoma, breast cancer, lung squamous cell cancer, and thyroid cancer (Wu et al., 2013; 23558953, Borad et al., 2014; 24550739). Gastric cancer patients with FGFR2 amplification were shown to have shorter overall survival (Matsumoto et al., 2012; 22240789). FGFR2 protein overexpression has been detected in various adenocarcinomas and has been associated with poorly differentiated tumors, aggressive disease, and shorter survival in some tumors (Giri et al., 1999; 10353739, Ishiwata et al., 2012; 22440254, Paterson et al., 2012; 22733579, Nomura et al., 2008; 18594526). FGFR2 signaling has been described as tumorigenic in lung, pancreatic, endometrial, and gastric cancers (Yamayoshi et al., 2004; 15307144, Cho et al., 2007; 17525264, Toyokawa et al., 2009; 19287982, Dutt et al., 2008; 18552176). However, FGFR2 has also been described as a tumor suppressor in the context of other cancers, such as melanoma (Gartside et al., 2009; 19147536). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), ICP192 (Guo et al., 2021; ASCO Abstract 4092), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). In the context of FGFR2 rearrangement, FGFR inhibitors have primarily been investigated for patients with previously treated intrahepatic cholangiocarcinoma (ICC), with the Phase 2 FIGHT_202 trial for pemigatinib (Abou_Alfa et al., 2020; 32203698) and a Phase 2 trial for infigratinib (Javle et al., 2021; ASCO GI Abstract 265) respectively reporting ORRs of 36% (38/107) and 23% (25/108). Responses to erdafitinib have been reported in patients with FGFR2 fusion_positive urothelial carcinoma (Siefker_Radtke et al., 2018; ASCO Abstract 4503) and endometrial carcinoma (Tabernero et al., 2015; 26324363).", "Include": "true", "ClinicalTrialNote": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Erdafitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Erdafitinib is a pan_fibroblast growth factor receptor (FGFR) inhibitor. It is FDA approved for the treatment of patients with advanced or metastatic urothelial carcinoma who have FGFR2 or FGFR3 alterations and have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence for FGFR2 fusions (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Park et al., 2019; ASCO Abstract 4117), limited evidence for FGFR2 mutations (Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117) and limited evidence for FGFR2 amplification (Bahleda et al., 2019; 31088831), and preclinical data (Perera et al., 2017; 28341788, Karkera et al., 2017; 28416604), FGFR2 activating alterations may confer sensitivity to erdafitinib. </p> <p><b>Supporting Data:</b> Erdafitinib has been primarily studied for the treatment of FGFR_altered urothelial carcinoma. A Phase 2 study evaluating erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (mUC) previously treated with chemotherapy and harboring FGFR2/3 fusions or FGFR3 activating mutations reported an ORR of 40% (40/99, 3 CR), and a DCR of 80% (79/99) (Loriot et al., 2019; 31340094). A Phase 1 trial of erdafitinib reported clinical responses in for patients with various FGFR2_ or FGFR3_altered solid tumors (Qin et al., 2019; 30267839, Soria et al., 2016; ASCO Abstract 4074, Tabernero et al., 2015; 26324363, Di Stefano et al., 2015; 25609060), including cholangiocarcinoma (27% ORR, 3/11), NSCLC (5% ORR, 1/21), breast (9% ORR, 3/34), and ovarian (9% ORR, 1/11), while other cancers including endometrial carcinoma and glioblastoma showed a low ORR (2%, 1/58)(Bahleda et al., 2019; 31088831). Following progression on multiple other lines of therapy, a patient with metastatic FGFR2_fusion_positive NSCLC treated with erdafitinib exhibited an 11_month PR (Qin et al., 2019; 30267839). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04083976", "Include": "true"}, {"nctId": "NCT03758664", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04189445", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT04008797", "Include": "true"}, {"nctId": "NCT03547037", "Include": "true"}, {"nctId": "NCT04042116", "Include": "true"}, {"nctId": "NCT04565275", "Include": "true"}, {"nctId": "NCT02272998", "Include": "true"}]}}, {"Name": "FGFR2_COL16A1 fusion", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "FGFR2_COL16A1 fusion"}}, "Interpretation": "FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 fusions retaining the kinase domain encoded by exons 11_17 have been reported to be activating, oncogenic, and sensitive to FGFR inhibitors (Singh et al., 2012; 22837387, Lorenzi et al., 1996; 8799135, Wu et al., 2013; 23558953, Arai et al., 2013; 24122810, Wu et al., 2013; 23558953). Furthermore, FGFR2 variants lacking a portion of the cytoplasmic domain encoded by exon 18 have been reported to be oncogenic in vitro (Lorenzi et al., 1997; 9266968, Lorenzi et al., 1996; 8799135, Ueda et al., 1999; 10626794, Wu et al., 2013; 23558953, Cha et al., 2009; 19103595). Rearrangements such as observed here are predicted to be activating. Rearrangements such as observed here, those that are detected as a reciprocal fusion, are not clearly in frame, or may lack a fusion partner, may be indicative of an activating rearrangement event such as a fusion; however, it is unclear whether such rearrangements would lead to an oncogenic FGFR2 fusion. FGFR2 fusions have been reported in 10_50% of intrahepatic cholangiocarcinoma patients (Ross et al., 2014; 24563076, Borad et al., 2014; 24550739, Arai et al., 2013; 24122810) and have also been observed in colorectal cancer, hepatocellular carcinoma, breast cancer, lung squamous cell cancer, and thyroid cancer (Wu et al., 2013; 23558953, Borad et al., 2014; 24550739). Gastric cancer patients with FGFR2 amplification were shown to have shorter overall survival (Matsumoto et al., 2012; 22240789). FGFR2 protein overexpression has been detected in various adenocarcinomas and has been associated with poorly differentiated tumors, aggressive disease, and shorter survival in some tumors (Giri et al., 1999; 10353739, Ishiwata et al., 2012; 22440254, Paterson et al., 2012; 22733579, Nomura et al., 2008; 18594526). FGFR2 signaling has been described as tumorigenic in lung, pancreatic, endometrial, and gastric cancers (Yamayoshi et al., 2004; 15307144, Cho et al., 2007; 17525264, Toyokawa et al., 2009; 19287982, Dutt et al., 2008; 18552176). However, FGFR2 has also been described as a tumor suppressor in the context of other cancers, such as melanoma (Gartside et al., 2009; 19147536). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), ICP192 (Guo et al., 2021; ASCO Abstract 4092), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). In the context of FGFR2 rearrangement, FGFR inhibitors have primarily been investigated for patients with previously treated intrahepatic cholangiocarcinoma (ICC), with the Phase 2 FIGHT_202 trial for pemigatinib (Abou_Alfa et al., 2020; 32203698) and a Phase 2 trial for infigratinib (Javle et al., 2021; ASCO GI Abstract 265) respectively reporting ORRs of 36% (38/107) and 23% (25/108). Responses to erdafitinib have been reported in patients with FGFR2 fusion_positive urothelial carcinoma (Siefker_Radtke et al., 2018; ASCO Abstract 4503) and endometrial carcinoma (Tabernero et al., 2015; 26324363).", "Include": "true", "ClinicalTrialNote": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Erdafitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Erdafitinib is a pan_fibroblast growth factor receptor (FGFR) inhibitor. It is FDA approved for the treatment of patients with advanced or metastatic urothelial carcinoma who have FGFR2 or FGFR3 alterations and have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence for FGFR2 fusions (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Park et al., 2019; ASCO Abstract 4117), limited evidence for FGFR2 mutations (Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117) and limited evidence for FGFR2 amplification (Bahleda et al., 2019; 31088831), and preclinical data (Perera et al., 2017; 28341788, Karkera et al., 2017; 28416604), FGFR2 activating alterations may confer sensitivity to erdafitinib. </p> <p><b>Supporting Data:</b> Erdafitinib has been primarily studied for the treatment of FGFR_altered urothelial carcinoma. A Phase 2 study evaluating erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (mUC) previously treated with chemotherapy and harboring FGFR2/3 fusions or FGFR3 activating mutations reported an ORR of 40% (40/99, 3 CR), and a DCR of 80% (79/99) (Loriot et al., 2019; 31340094). A Phase 1 trial of erdafitinib reported clinical responses in for patients with various FGFR2_ or FGFR3_altered solid tumors (Qin et al., 2019; 30267839, Soria et al., 2016; ASCO Abstract 4074, Tabernero et al., 2015; 26324363, Di Stefano et al., 2015; 25609060), including cholangiocarcinoma (27% ORR, 3/11), NSCLC (5% ORR, 1/21), breast (9% ORR, 3/34), and ovarian (9% ORR, 1/11), while other cancers including endometrial carcinoma and glioblastoma showed a low ORR (2%, 1/58)(Bahleda et al., 2019; 31088831). Following progression on multiple other lines of therapy, a patient with metastatic FGFR2_fusion_positive NSCLC treated with erdafitinib exhibited an 11_month PR (Qin et al., 2019; 30267839). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04083976", "Include": "true"}, {"nctId": "NCT03758664", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04189445", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT04008797", "Include": "true"}, {"nctId": "NCT03547037", "Include": "true"}, {"nctId": "NCT04042116", "Include": "true"}, {"nctId": "NCT04565275", "Include": "true"}, {"nctId": "NCT02272998", "Include": "true"}]}}]}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "03", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "03"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of TMB have mainly been investigated in the context of tissue TMB. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. While approximately 80% of MSI_H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 659_672+15del29", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 659_672+15del29"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Pan_cancer analysis of the TCGA datasets across 12 cancer types identified TP53 as the most frequently mutated gene, with 42% of more than 3,000 tumors harboring a TP53 mutation; in this study TP53 mutation occurred most frequently in ovarian serous carcinoma (95%), lung squamous cell carcinoma (SCC) (79%), head and neck SCC (70%), colorectal adenocarcinoma (59%), lung adenocarcinoma (52%), and bladder urothelial carcinoma (50%) (Kandoth et al., 2013; 24132290). TP53 loss of heterozygosity (LOH) is frequently seen in tumors and often occurs when one copy of TP53 harbors a mutation; in some tumors, LOH is correlated with progression (Wongsurawat et al., 2006; 16537709, Brosh and Rotter, 2009; 19693097, Baker et al., 1989; 2649981, Calcagno et al., 2013; 24053468). While the prognostic significance of TP53 alteration or dysregulation varies according to tumor type, studies have shown an association with poor prognosis for patients with breast cancer (Alsner et al., 2008; 18465328, Olivier et al., 2006; 16489069, V\u00e9gran et al., 2013; 23359294), endometrial cancer (Wild et al., 2012; 22678923, Lee et al., 2010; 20006376), HNSCC (Ganci et al., 2013; 24107801, Lindenbergh_van et al., 2011; 21467160, Peltonen et al., 2011; 21513535), or urothelial cancer (Bringuier et al., 1998; 9761125, Feng et al., 2014; 24500328). In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD_L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD_1 inhibitors pembrolizumab and nivolumab in this study (Dong et al., 2016; 28039262). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations", "StudyPhase": "PHASE 2", "Target": "FGFRs", "Locations": "Taipei (Taiwan), Taoyuan City (Taiwan), Taichung (Taiwan), Changhua (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Kaohsiung (Taiwan), Hangzhou (China), Shanghai (China), Nanjing (China)", "NCTID": "NCT04083976", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "Clinical Study of ICP_192 in Solid Tumors Patients", "StudyPhase": "PHASE 1/2", "Target": "FGFR2, FGFR1, FGFR3, FGFR4", "Locations": "Shanghai (China)", "NCTID": "NCT03758664", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "Futibatinib in Patients With Specific FGFR Aberrations", "StudyPhase": "PHASE 2", "Target": "FGFRs", "Locations": "Seul (Korea, Republic of), Sapporo_shi (Japan), London (United Kingdom), California, Arizona, Wisconsin, Texas", "NCTID": "NCT04189445", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)", "StudyPhase": "PHASE 1", "Target": "ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Seoul (Korea, Republic of), Tokyo (Japan), Haifa (Israel), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington", "NCTID": "NCT03564691", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor", "StudyPhase": "PHASE 1", "Target": "CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Osakasayama (Japan), Chuo_Ku (Japan), Kashiwa (Japan)", "NCTID": "NCT04008797", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ_63723283, an Anti_Programmed Cell Death (PD)_1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers", "StudyPhase": "PHASE 1", "Target": "PD_1, FGFRs", "Locations": "Chuo_Ku (Japan), Kashiwa (Japan)", "NCTID": "NCT03547037", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor", "StudyPhase": "PHASE 1/2", "Target": "FGFRs, VEGFRs, PD_1", "Locations": "Innsbruck (Austria), Essen (Germany), Bologna (Italy), Naples (Italy), Leuven (Belgium), Brussels (Belgium), Ghent (Belgium), Washington, Barcelona (Spain), Madrid (Spain)", "NCTID": "NCT04042116", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "A Study of ICP_192 in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFR2, FGFR1, FGFR3, FGFR4", "Locations": "Colorado, Minnesota, Arizona, Florida", "NCTID": "NCT04565275", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "GRM4_FGFR2 rearrangementFGFR2_COL16A1 fusion", "Title": "Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.", "StudyPhase": "PHASE 2", "Target": "FGFRs, VEGFRs, ABL, RET, FLT3, KIT", "Locations": "Ohio", "NCTID": "NCT02272998", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "11021964", "FullCitation": "Powers CJ, et al. Endocr. Relat. Cancer (2000) pmid: 11021964", "Include": "true"}, {"number": "1", "ReferenceId": "20094046", "FullCitation": "Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046", "Include": "true"}, {"number": "2", "ReferenceId": "22837387", "FullCitation": "Singh D, et al. Science (2012) pmid: 22837387", "Include": "true"}, {"number": "3", "ReferenceId": "8799135", "FullCitation": "Lorenzi MV, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8799135", "Include": "true"}, {"number": "4", "ReferenceId": "23558953", "FullCitation": "Wu YM, et al. Cancer Discov (2013) pmid: 23558953", "Include": "true"}, {"number": "5", "ReferenceId": "24122810", "FullCitation": "Arai Y, et al. Hepatology (2014) pmid: 24122810", "Include": "true"}, {"number": "6", "ReferenceId": "9266968", "FullCitation": "Lorenzi MV, et al. Oncogene (1997) pmid: 9266968", "Include": "true"}, {"number": "7", "ReferenceId": "10626794", "FullCitation": "Ueda T, et al. Cancer Res. (1999) pmid: 10626794", "Include": "true"}, {"number": "8", "ReferenceId": "19103595", "FullCitation": "Cha JY, et al. J. Biol. Chem. (2009) pmid: 19103595", "Include": "true"}, {"number": "9", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "10", "ReferenceId": "24550739", "FullCitation": "Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739", "Include": "true"}, {"number": "11", "ReferenceId": "22240789", "FullCitation": "Matsumoto K, et al. Br. J. Cancer (2012) pmid: 22240789", "Include": "true"}, {"number": "12", "ReferenceId": "10353739", "FullCitation": "Giri D, et al. Clin. Cancer Res. (1999) pmid: 10353739", "Include": "true"}, {"number": "13", "ReferenceId": "22440254", "FullCitation": "Ishiwata T, et al. Am. J. Pathol. (2012) pmid: 22440254", "Include": "true"}, {"number": "14", "ReferenceId": "22733579", "FullCitation": "Paterson AL, et al. J. Pathol. (2013) pmid: 22733579", "Include": "true"}, {"number": "15", "ReferenceId": "18594526", "FullCitation": "Nomura S, et al. Br. J. Cancer (2008) pmid: 18594526", "Include": "true"}, {"number": "16", "ReferenceId": "15307144", "FullCitation": "Yamayoshi T, et al. J. Pathol. (2004) pmid: 15307144", "Include": "true"}, {"number": "17", "ReferenceId": "17525264", "FullCitation": "Cho K, et al. Am. J. Pathol. (2007) pmid: 17525264", "Include": "true"}, {"number": "18", "ReferenceId": "19287982", "FullCitation": "Toyokawa T, et al. Oncol. Rep. (2009) pmid: 19287982", "Include": "true"}, {"number": "19", "ReferenceId": "18552176", "FullCitation": "Dutt A, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18552176", "Include": "true"}, {"number": "20", "ReferenceId": "19147536", "FullCitation": "Gartside MG, et al. Mol. Cancer Res. (2009) pmid: 19147536", "Include": "true"}, {"number": "21", "ReferenceId": "26324363", "FullCitation": "Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363", "Include": "true"}, {"number": "22", "ReferenceId": "31371345", "FullCitation": "Krook MA, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 31371345", "Include": "true"}, {"number": "23", "ReferenceId": "32203698", "FullCitation": "Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32203698", "Include": "true"}, {"number": "24", "ReferenceId": "27870574", "FullCitation": "Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574", "Include": "true"}, {"number": "25", "ReferenceId": "27179038", "FullCitation": "Pearson A, et al. Cancer Discov (2016) pmid: 27179038", "Include": "true"}, {"number": "26", "ReferenceId": "29177434", "FullCitation": "Van Cutsem E, et al. Ann. Oncol. (2017) pmid: 29177434", "Include": "true"}, {"number": "27", "ReferenceId": "31195180", "FullCitation": "Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180", "Include": "true"}, {"number": "28", "ReferenceId": "30745300", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300", "Include": "true"}, {"number": "29", "ReferenceId": "33926920", "FullCitation": "Cleary JM, et al. Cancer Discov (2021) pmid: 33926920", "Include": "true"}, {"number": "30", "ReferenceId": "31405822", "FullCitation": "Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822", "Include": "true"}, {"number": "31", "ReferenceId": "31109923", "FullCitation": "Goyal L, et al. Cancer Discov (2019) pmid: 31109923", "Include": "true"}, {"number": "32", "ReferenceId": "30420614", "FullCitation": "Mazzaferro V, et al. Br. J. Cancer (2019) pmid: 30420614", "Include": "true"}, {"number": "33", "ReferenceId": "23786770", "FullCitation": "Liao RG, et al. Cancer Res. (2013) pmid: 23786770", "Include": "true"}, {"number": "34", "ReferenceId": "22238366", "FullCitation": "Gozgit JM, et al. Mol. Cancer Ther. (2012) pmid: 22238366", "Include": "true"}, {"number": "35", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "36", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "37", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "38", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "39", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "40", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "41", "ReferenceId": "24132290", "FullCitation": "Kandoth C, et al. Nature (2013) pmid: 24132290", "Include": "true"}, {"number": "42", "ReferenceId": "16537709", "FullCitation": "Wongsurawat VJ, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16537709", "Include": "true"}, {"number": "43", "ReferenceId": "19693097", "FullCitation": "Brosh R, et al. Nat. Rev. Cancer (2009) pmid: 19693097", "Include": "true"}, {"number": "44", "ReferenceId": "2649981", "FullCitation": "Baker SJ, et al. Science (1989) pmid: 2649981", "Include": "true"}, {"number": "45", "ReferenceId": "24053468", "FullCitation": "Calcagno DQ, et al. BMC Gastroenterol (2013) pmid: 24053468", "Include": "true"}, {"number": "46", "ReferenceId": "18465328", "FullCitation": "Alsner J, et al. Acta Oncol (2008) pmid: 18465328", "Include": "true"}, {"number": "47", "ReferenceId": "16489069", "FullCitation": "Olivier M, et al. Clin. Cancer Res. (2006) pmid: 16489069", "Include": "true"}, {"number": "48", "ReferenceId": "23359294", "FullCitation": "V\u00e9gran F, et al. PLoS ONE (2013) pmid: 23359294", "Include": "true"}, {"number": "49", "ReferenceId": "22678923", "FullCitation": "Wild PJ, et al. EMBO Mol Med (2012) pmid: 22678923", "Include": "true"}, {"number": "50", "ReferenceId": "20006376", "FullCitation": "Lee EJ, et al. Gynecol. Oncol. (2010) pmid: 20006376", "Include": "true"}, {"number": "51", "ReferenceId": "24107801", "FullCitation": "Ganci F, et al. Ann. Oncol. (2013) pmid: 24107801", "Include": "true"}, {"number": "52", "ReferenceId": "21467160", "FullCitation": "Lindenbergh_van der Plas M, et al. Clin. Cancer Res. (2011) pmid: 21467160", "Include": "true"}, {"number": "53", "ReferenceId": "21513535", "FullCitation": "Peltonen JK, et al. Head Neck Oncol (2011) pmid: 21513535", "Include": "true"}, {"number": "54", "ReferenceId": "9761125", "FullCitation": "Bringuier PP, et al. Int. J. Cancer (1998) pmid: 9761125", "Include": "true"}, {"number": "55", "ReferenceId": "24500328", "FullCitation": "Feng C, et al. Sci Rep (2014) pmid: 24500328", "Include": "true"}, {"number": "56", "ReferenceId": "28039262", "FullCitation": "Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262", "Include": "true"}, {"number": "57", "ReferenceId": "16172461", "FullCitation": "Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461", "Include": "true"}, {"number": "58", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "59", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "60", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "61", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "62", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "63", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "64", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "65", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "66", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "67", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "68", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "69", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "70", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "71", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "72", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "73", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "74", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "75", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "76", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "77", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "78", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "79", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "80", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "81", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "82", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "83", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "84", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "85", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "86", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "87", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "88", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "89", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "90", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "91", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "92", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "93", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "94", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "95", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "96", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "97", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "98", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "99", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "100", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "101", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "102", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "103", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "104", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "105", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "106", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "107", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "108", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "109", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "110", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "111", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "112", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "113", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "114", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "115", "ReferenceId": "27022117", "FullCitation": "Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117", "Include": "true"}, {"number": "116", "ReferenceId": "11535541", "FullCitation": "Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541", "Include": "true"}, {"number": "117", "ReferenceId": "12445368", "FullCitation": "Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368", "Include": "true"}, {"number": "118", "ReferenceId": "12820457", "FullCitation": "Brueckl WM, et al. Anticancer Res. () pmid: 12820457", "Include": "true"}, {"number": "119", "ReferenceId": "11438476", "FullCitation": "Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476", "Include": "true"}, {"number": "120", "ReferenceId": "10631274", "FullCitation": "Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274", "Include": "true"}, {"number": "121", "ReferenceId": "16952542", "FullCitation": "Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542", "Include": "true"}, {"number": "122", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "123", "ReferenceId": "22722556", "FullCitation": "Laghi L, et al. Dig Dis (2012) pmid: 22722556", "Include": "true"}, {"number": "124", "ReferenceId": "27159395", "FullCitation": "Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395", "Include": "true"}, {"number": "125", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "126", "ReferenceId": "23528559", "FullCitation": "Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559", "Include": "true"}, {"number": "127", "ReferenceId": "24777035", "FullCitation": "Cazier JB, et al. Nat Commun (2014) pmid: 24777035", "Include": "true"}, {"number": "128", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "129", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "130", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "131", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "132", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "133", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "134", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "135", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "136", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "137", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "138", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "139", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "140", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "141", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "142", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "143", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "144", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "145", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "146", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "147", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "148", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "149", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "150", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "151", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "152", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "153", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "154", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "155", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "156", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "157", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "158", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "159", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "160", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "161", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "162", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "163", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "164", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "165", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "166", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "167", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "168", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "169", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "170", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "171", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "172", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "173", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "174", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "175", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "176", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "177", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "178", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "179", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "180", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "181", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "182", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "183", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "184", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "185", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "186", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "187", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "188", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "189", "ReferenceId": "19659756", "FullCitation": "Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756", "Include": "true"}, {"number": "190", "ReferenceId": "22714864", "FullCitation": "Pande M, et al. Fam. Cancer (2012) pmid: 22714864", "Include": "true"}, {"number": "191", "ReferenceId": "17920897", "FullCitation": "Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897", "Include": "true"}, {"number": "192", "ReferenceId": "19466295", "FullCitation": "Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295", "Include": "true"}, {"number": "193", "ReferenceId": "24978665", "FullCitation": "Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665", "Include": "true"}, {"number": "194", "ReferenceId": "16136383", "FullCitation": "Fam. Cancer (2005) pmid: 16136383", "Include": "true"}, {"number": "195", "ReferenceId": "31340094", "FullCitation": "Loriot Y, et al. N. Engl. J. Med. (2019) pmid: 31340094", "Include": "true"}, {"number": "196", "ReferenceId": "30267839", "FullCitation": "Qin A, et al. J Thorac Oncol (2019) pmid: 30267839", "Include": "true"}, {"number": "197", "ReferenceId": "25609060", "FullCitation": "Di Stefano AL, et al. Clin. Cancer Res. (2015) pmid: 25609060", "Include": "true"}, {"number": "198", "ReferenceId": "31088831", "FullCitation": "Bahleda R, et al. Clin. Cancer Res. (2019) pmid: 31088831", "Include": "true"}, {"number": "199", "ReferenceId": "28341788", "FullCitation": "Perera TPS, et al. Mol. Cancer Ther. (2017) pmid: 28341788", "Include": "true"}, {"number": "200", "ReferenceId": "28416604", "FullCitation": "Karkera JD, et al. Mol. Cancer Ther. (2017) pmid: 28416604", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_01_16 23:01:59", "OpName": "Leah Commander, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Leah Commander, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "3 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": {"comment": {"commentedBy": "Leah Commander, M.D.", "commentedDts": "2022_01_16T23:01:08.000Z", "text": "A FGFR2 rearrangement and fusion are detected, which are most commonly associated with intrahepatic cholangiocarcinoma. Pemigatinib is an approved therapy for cholangiocarcinoma with these FGFR2 alterations. Clinicopathologic and genomic correlation is recommended."}}, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary carcinoma (NOS)", "flowcell_analysis": "2000019608", "gender": "male", "pathology_diagnosis": "Carcinoma", "pipeline_version": "v3.10.0", "purity_assessment": "15.0", "specimen": "ORD_1273243_01*US1223101.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1273243_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1223101.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0044", "cds_effect": "292G>A", "depth": "4107", "equivocal": "false", "functional_effect": "missense", "gene": "CHEK2", "percent_reads": "0.44", "position": "chr22:29130418", "protein_effect": "A98T", "status": "unknown", "strand": "_", "transcript": "NM_007194", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.4336", "cds_effect": "410C>T", "depth": "1852", "equivocal": "false", "functional_effect": "missense", "gene": "CD22", "percent_reads": "43.36", "position": "chr19:35823825", "protein_effect": "S137F", "status": "unknown", "strand": "+", "transcript": "NM_001771", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.0485", "cds_effect": "659_672+15del29", "depth": "4887", "equivocal": "false", "functional_effect": "splice", "gene": "TP53", "percent_reads": "4.85", "position": "chr17:7578161", "protein_effect": "splice site 659_672+15del29", "status": "likely", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.0044", "cds_effect": "3914C>A", "depth": "907", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5A", "percent_reads": "0.44", "position": "chr12:416636", "protein_effect": "A1305D", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.4947", "cds_effect": "1418A>G", "depth": "2276", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "49.47", "position": "chr3:49936509", "protein_effect": "Q473R", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.4561", "cds_effect": "2729G>A", "depth": "353", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "45.61", "position": "chr5:38953624", "protein_effect": "R910H", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.4865", "cds_effect": "1595C>T", "depth": "1591", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "48.65", "position": "chr7:2969684", "protein_effect": "T532M", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.5787", "cds_effect": "893C>T", "depth": "4230", "equivocal": "false", "functional_effect": "missense", "gene": "MAP2K2", "percent_reads": "57.87", "position": "chr19:4099225", "protein_effect": "P298L", "status": "unknown", "strand": "_", "transcript": "NM_030662", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.0293", "cds_effect": "68A>T", "depth": "1094", "equivocal": "false", "functional_effect": "missense", "gene": "PPP2R2A", "percent_reads": "2.93", "position": "chr8:26151242", "protein_effect": "D23V", "status": "unknown", "strand": "+", "transcript": "NM_002717", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.0344", "cds_effect": "5592C>G", "depth": "1510", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "3.44", "position": "chr12:133214686", "protein_effect": "I1864M", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.4943", "cds_effect": "428G>A", "depth": "1133", "equivocal": "false", "functional_effect": "missense", "gene": "POLD1", "percent_reads": "49.43", "position": "chr19:50905146", "protein_effect": "G143D", "status": "unknown", "strand": "+", "transcript": "NM_002691", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": [{"allele_fraction": "0.0191", "description": "FGFR2(NM_000141)_COL16A1(NM_001856) fusion (F17; C65)", "equivocal": "false", "in_frame": "Yes", "other_gene": "COL16A1", "percent_reads": "1.91", "pos1": "chr10:123242198", "pos2": "chr1:32123767", "status": "likely", "supporting_read_pairs": "80", "targeted_gene": "FGFR2", "type": "fusion", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"allele_fraction": "0.0389", "description": "FGFR2(NM_000141) rearrangement intron 17", "equivocal": "false", "in_frame": "unknown", "other_gene": "GRM4", "percent_reads": "3.89", "pos1": "chr10:123242270", "pos2": "chr6:34116827", "status": "likely", "supporting_read_pairs": "166", "targeted_gene": "FGFR2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.53", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HHV_8", "reads_per_million": "12", "status": "unknown", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"organism": "HPV_16", "reads_per_million": "16", "status": "unknown", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}, {"organism": "HHV_4", "reads_per_million": "29", "status": "unknown", "dna_evidence": {"sample": "SQ_US1223101.01_1"}}]}}}}}